

**APA150Hu02 100µg**  
**Active Carcinoembryonic Antigen (CEA)**  
**Organism Species: *Homo sapiens* (Human)**  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Ala566~Gly698

**Tags:** N-terminal His-tag

**Purity:** >98%

**Endotoxin Level:** <1.0EU per 1µg (determined by the LAL method).

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 5.9

**Predicted Molecular Mass:** 15.0kDa

**Accurate Molecular Mass:** 16/25kDa as determined by SDS-PAGE reducing conditions.

### **Phenomenon explanation:**

The possible reasons that the actual band size differs from the predicted are as follows:

1. Splice variants: Alternative splicing may create different sized proteins from the same gene.
2. Relative charge: The composition of amino acids may affects the charge of the protein.
3. Post-translational modification: Phosphorylation, glycosylation, methylation etc.
4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to give the active form.
5. Polymerization of the target protein: Dimerization, multimerization etc.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.


## **[ SEQUENCE ]**

```
ARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIIISP  
PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN  
GTYACFVSNL ATGRNNSIVK SITVSASGTS PGLSAGATVG IMIGVLVG
```

## **[ ACTIVITY ]**


Carcinoembryonic antigen (CEA) which are characterized as members of the CD66 cluster of differentiation have highly related glycoproteins involved in cell adhesion. It also can be used as a tumor marker in clinical tests. CEA are glycosyl phosphatidyl inositol (GPI) cell-surface-anchored glycoproteins whose specialized sialofucosylated glycoforms serve as functional colon carcinoma L-selectin and E-selectin ligands. Besides, Galectin 4 (GAL4) has been identified as an interactor of CEA, thus a binding ELISA assay was conducted to detect the interaction of recombinant human CEA and recombinant human GAL4. Briefly, CEA were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to GAL4-coated microtiter wells and incubated for 2h at 37°C. Wells

were washed with PBST and incubated for 1h with anti-CEA pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of CEA and GLA4 was shown in Figure 1, and this effect was in a dose dependent manner.




**Figure 1. The binding activity of CEA with GLA4.**

## [ IDENTIFICATION ]



**Figure 2. Gene Sequencing (extract)**



**Figure 3. SDS-PAGE**

**Sample: Active recombinant CEA, Human**

**[ IMPORTANT NOTE ]**

The kit is designed for in vitro and research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.